EP0354638A2 — Use of adenosine and its derivatives in diagnosis
Assigned to MedCo Research Inc · Expires 1990-02-14 · 36y expired
What this patent protects
The invention comprises the use, in the preparation of a diagnostic agent for parenteral administration to humans, of adenosine a functional adenosine receptor agonist including 1-methyl-2-phenylethyl adenosine, 5-ethyl carboxamide adenosine, cyclopentyl adenosine and 2-chloro a…
USPTO Abstract
The invention comprises the use, in the preparation of a diagnostic agent for parenteral administration to humans, of adenosine a functional adenosine receptor agonist including 1-methyl-2-phenylethyl adenosine, 5-ethyl carboxamide adenosine, cyclopentyl adenosine and 2-chloro adenosine; a metabolic precursor or by-product of adenosine including adenine and inosine; or a phosphorylated derivative of adenosine including adenosine monophosphate, adenosine diphosphate and adenosine triphosphate. The diagnostic agent is used in detecting the presence, or assessing the severity, of vascular disease.
Drugs covered by this patent
- regadenoson (Regadenoson) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.